Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
about
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Chimeric antigen receptor T-cell therapies for lymphoma.Adoptive Cell Therapy in Multiple Myeloma.Recent developments in immunotherapy of acute myeloid leukemia.Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.Cancer Immunotherapies: Are They as Effective in the Elderly?Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.The Antibodies: What a Universe!Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment conceptsTransplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap.Clinical trials of CAR-T cells in ChinaTherapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy.Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy.Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma.Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.CAR-T cells: the narrow path between hope and bankruptcy?Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.Current Status of Gene Engineering Cell Therapeutics.A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction.Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report.IL-2 and Beyond in Cancer Immunotherapy.Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.The Pharmacology of T Cell Therapies.CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
P2860
Q33823270-ACACD2C3-D8FE-492B-9B3C-F68AC0A002BDQ38600697-D6EA3B97-93C3-4861-86FA-84071683A6E7Q38635138-7055A2E6-FEEE-4FCD-B3D9-418AD4FD5385Q38661895-96EA1BFF-A949-4918-BA9F-9CFFD9F30F0EQ38666256-28E68CFA-F22A-460F-8D53-BCE3E11FD926Q38679662-E5B94EEE-8098-43B8-BE19-7E82B4D48675Q39418546-42075337-49D9-4701-AD09-7B1BCB4EECF9Q40095482-91D185C1-0F4D-4DCB-872B-051B95256F82Q41269380-51D52EB1-BBCA-41ED-A7C3-8A37DFC901E1Q41541605-F6A9EF2B-C37A-4D08-850B-62CDB1DBCA55Q41600980-24AAD549-8E2B-411F-8BAE-5F5ED416AC90Q42334095-DF48D8C1-BCD1-4F5C-B034-72CDFC57A758Q42654456-ABDD36F6-ACC6-4CFC-ADB2-D179DBF34E61Q43525091-FAF12EB8-28D1-47F1-A99C-008585D7556CQ45864030-D318439B-23EC-4F18-82EB-8EE492E504DAQ45867205-8279F998-3166-47D4-B0B5-C49619808229Q45871879-EA3B6620-3B35-4D39-9264-5043E0A6A49CQ45875529-A6D9AF2A-DDCD-4CE7-84E1-6890F237AB36Q46082373-F4B44D5E-BF3B-4B39-B799-553F831D5E2FQ46438521-877E4523-24C2-428A-AE98-D9E3195309D6Q47193084-6F05A9BE-4901-418C-9BBA-761AC9FA1A0DQ47271647-D6160FE1-44B2-4127-9652-A1A10794E21BQ47332598-63ED5714-A9E6-45AB-B002-F82B61841A4AQ47563525-6A0913B6-C523-423E-9013-3387CE4D568CQ47629566-C3BF1B92-7449-452D-9081-5702FB9018BAQ47681829-3AEDC816-623A-4441-859B-E5D2D0035D3CQ47682409-93CB1AEE-87E5-4822-94F6-6BFB34F53220Q48255324-D8E873B2-FF55-42BC-8F5E-0C6BD471D7C1Q49391681-073989E5-0828-4407-B765-27C922D86F46Q49722635-9EBA8CFD-73F6-4455-956E-1A9DBEA1A562Q49829282-BAF0BDC1-ED33-45EE-A8DA-7EE52EE66511Q49894698-D8CCBE8B-8A40-4AD2-9F6F-7F9A608BC741Q50003042-1FB84399-75B6-4DD0-ADFE-BAD18C8F5CE9Q50004232-57301A62-2E37-40D6-88C4-422786E13658Q50027358-7D9506F0-C905-4B1A-AD27-6FB6FDC75B8DQ52588132-CBAE0461-D9C7-4C10-91C3-A8E5BC4F52C9Q52780137-4B51B167-0EEC-4DA9-B909-59CF055F8576Q54965295-C57032C4-02E5-4962-8B8E-8CD974DEFFB0Q54985631-032A3C29-65D0-4351-B71D-0B4EF3664828Q55193924-DBE97060-6110-4AD9-9F41-4DB4804E4C3D
P2860
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@en
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@nl
type
label
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@en
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@nl
prefLabel
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@en
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@nl
P2093
P2860
P1433
P1476
Phase 1 Results of ZUMA-1: A M ...... efractory Aggressive Lymphoma.
@en
P2093
Adrian Bot
Allen X Xue
Armin Ghobadi
Chitra M Hosing
Frederick L Locke
Jeff Aycock
Jeff Wiezorek
John M Rossi
Julio C Chavez
Lihua E Budde
P2860
P304
P356
10.1016/J.YMTHE.2016.10.020
P577
2017-01-04T00:00:00Z